Immune effector functions of human IgG2 antibodies against ... · 10/3/2018 · Rösner et al: Effector functions of IgG2 1 Immune effector functions of human IgG2 antibodies against
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Rösner et al: Effector functions of IgG2
1
Immune effector functions of human IgG2 antibodies against EGFR
Thies Rösner1*, Steffen Kahle1*, Francesca Montenegro1, Hanke L. Matlung2, J. H. Marco
Jansen3, Mitchell Evers3, Frank Beurskens4, Jeanette H.W. Leusen3, Timo K. van den Berg25,
Thomas Valerius1#
1 Section for Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian Albrechts University and University Hospital Schleswig-Holstein, Campus Kiel 2 Sanquin Research, Landsteiner Laboratory and Department of Molecular Cell Biology and Immunology, VU Medical Center, Amsterdam, The Netherlands 3 Laboratory of Translational Immunology, University Medical Center, Utrecht, The Netherlands
4 Genmab BV, Utrecht, The Netherlands 5 Dept. Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands
* these authors contributed equally
# Corresponding author: Thomas Valerius, MD; Section for Stem Cell Transplantation and
Immunotherapy, Department of Medicine II, Christian Albrechts University and University
Hospital Schleswig-Holstein, Campus Kiel, Arnold Heller Str. 3, 24105 Kiel, Germany; phone:
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
1. Sharma P, Allison JP. The future of immune checkpoint blockade. Science. 2015;348:56-61.
2. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321-30.
3. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, KIm DH, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938-45.
4. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-asociated neutrophil (TAN) phenotype by TGF-ß: "N1" versus "N2" TAN Cancer Cell. 2009;16:183-94.
5. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164:6166-73.
6. Matlung HL, Szilagyi K, Barclay NA, van den Berg TK. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017;276:145-64.
7. Weiskopf K, Weissman I, L. Macrophages as critical effectors for antibody therapy of cancer. mAbs. 2015;7:303-10.
8. Bournazos S, Wang TT, Ravetch JV. The role and function of Fc receptors on myeloid cells. Microbiol Spectr. 2017;4(6). doi: 10.1128.
9. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34-47.
10. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificty and
affinities of human Fc receptors and their polymophic variants for human IgG subclasses. Blood. 2009;113:3716-25.
11. Derer S, Glorius P, Schlaeth M, Lohse S, Klausz K, Muchhal U, et al. Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity. mAbs. 2014;6:409-21.
12. Parren PWHI, Warmerdam PAM, Boeije LCM, Arts J, Westerdaal NAC, Vlug A, et al. On the
interaction of IgG subclasses with the low affinity FcRIIa (CD32) on human monocytes, neutrophils, and platelets; analysis of a functional polymorphism to human IgG2. J Clin Invest. 1992;90:1537-46.
13. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100:1059-70.
14. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc γ receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hemato Oncol. 2013;6:1.
15. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443-6.
16. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor- dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199:1659-69.
17. Schewe DM, Alsadeq A, Sattler C, Lenk L, Vogiatzi F, Cario G, et al. An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts. Blood. 2017;130:1543-52.
18. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:1-17.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
19. Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2018;18:46-61.
20. Kaplon H, Reichert JM. Antibodies to watch in 2018. mAbs. 2018:1-21.
21. Brüggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med. 1987;166:1351-61.
22. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PHC, Derer S, et al. Human IgG2 antibodies against epidermal growth factor effectively trigger ADCC but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol. 2010;184:512-20.
23. Garred P, Michaelsen TE, Aases A. The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration. Scand J Immunol. 1989;30:379-82.
24. Valim YML, Lachmann PJ. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol. 1991;84:1-8.
25. Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, et al. Complement- dependent tumor cell lysis triggered by combinations of EGF-R antibodies. Cancer Res. 2008;68:4998-5003.
26. Mendelsohn J. Targeting the epidermal growth factor receptor. J Clin Oncol. 2002;20:1s-13s.
27. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25:282-303.
28. Vink T, Oudshoorn-Dickmann M, Roza M, Reitsma JJ, de Jong RN. A simple, robust and highly efficient transient expression system for producing antibodies. Methods. 2014;65:5-10.
29. Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, et al. Neutrophils kill antibody-opsonized cancer cells by trogoptosis. Cell Rep. 2018;23:3946-3959.
30. Derer S, Bauer P, Lohse S, Scheel AH, Berger S, Kellner C, et al. Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechansims of EGFR antibodies. J Immunol. 2012;189:5230-9.
31. Zhao XW, van Beck EM, Schornagel K, van der Maaden H, van Houdt M, Otten MA, et al.
CD47-signal regulatory protein-α (SIRP) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci USA. 2011;108:18342-7.
32. Dillon TM, Ricci MS, Vezina C, Flynn GC, Liu YD, Rehder DS, et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem. 2008;283:16206-15.
33. White AL, Chan HTC, French RF, Willoughby J, Mockridge CI, Roghanian A, et al. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatoty anticancer antibodies. Cancer Cell. 2015;27:1-11.
34. Konitzer JD, Sieron A, Wacker A, Enenkel B. Reformatting Rituximab into human IgG2 and IgG4 isotypes dramatically improves apoptosis induction in vitro. PloS One. 2015;10:e0145633.
35. Yu X, Chan HTC, Orr CM, Dadas O, Booth SG, Dahal LN, et al. Complex interplay between epitope specificity and isotype dictates the biological activity of anti-human CD40 antibodies. Cancer Cell. 2018.
36. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7:301-11.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
37. Schmiedel J, Blaukat A, Li S, Knochel T, Ferguson KM. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell. 2008;13:365-73.
38. Sickmier EA, Kurzeja RJ, Michelsen K, Vazir M, Yang E, Tasker AS. The Panitumumab EGFR complex reveals a binding mechanism that overcomes Cetuximab induced resistance. PloS One. 2016;11:e0163366.
39. Lammerts van Bueren JJ, Bleeker WK, Brannstrom A, von Euler A, Jansson M, Peipp M, et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci USA. 2008;105:6109-14.
40. Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5/CD3 and is a requirement for myeloma cell killing. Cancer Cell. 2017;31:383-95.
41. Cleary KLS, Chan HTC, James S, Glennie MJ, Cragg MS. Antibody distance from the cell membrane regulates antibody effector mechanisms. J Immunol. 2017;198:3999-4011.
42. Velmurugan R, Challa DK, Ram S, Ober RJ, Ward ES. Macrophage-mediated trogocytosis leads to death of antibody-opsonized tumor cells. Mol Cancer Ther. 2016;15:1879-89.
43. Derer S, Cossham M, Rosner T, Kellner C, Beurskens FJ, Schwanbeck R, et al. A complement-optimized EGFR antibody improves cytotoxic functions of polymorphonuclear cells against tumor cells. J Immunol. 2015;195:5077-87.
44. Tammen A, Derer S, Schwanbeck R, Rosner T, Kretschmer A, Beurskens FJ, et al. Monoclonal antibodies against epidermal growth factor receptor acquire an ability to kill tumor cells through complement activation by mutations that selectively facilitate the hexamerization of IgG on opsonized cells. J Immunol. 2017;198:1585-94.
45. Sanchez-Martin FJ, Bellosillo B, Gelabert-Baldrich M, Dalmases A, Canadas I, Vidal J, et al. The first-in-class anti-EGFR antibody mixture Sym004 overcomes Cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer. Clin Cancer Res. 2016;22:3260-7.
46. Arena S, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med. 2016;8:324ra14.
47. Jacobsen HJ, Poulsen TT, Dahlman A, Kjaer I, Koefoed K, Sen JW, et al. Pan-HER, an antibody mixture simultaneously targeting EGFR, HER2, and HER3, effectively overcomes tumor heterogeneity and plasticity. Clin Cancer Res. 2015;21:4110-22.
48. Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014;343:1260-3.
49. de Jong RN, Beurskens FJ, Verploegen S, Strumane K, van Kampen MD, Voorhorst M, et al. A Novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biol. 2016;14:e1002344.
50. Krampitz GW, George BM, Willingham SB, Volkmer JP, Weiskopf K, Jahchan N, et al. Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proc Natl Acad Sci USA. 2016;113:4464-9.
51. Eruslanov EB. Phenotype and function of tumor-associated neutrophils and their subsets in early-stage human lung cancer. Cancer Immunol Immunother. 2017;66:997-1006.
52. Boross P, Lohse S, Nederend M, Jansen JHM, van Tetering G, Dechant M, et al. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med. 2013;5:1213-26.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
53. Lohse S, Meyer S, Meulenbroek LA, Jansen JHW, Nederend M, Kretschmer A, et al. An anti-EGFR IgA that displays improved pharmacokinetics and myeloid effector cell engagement in vivo. Cancer Res. 2016;76:403-17.
54. Leusen JHW. IgA as therapeutic antibody. Mol Immunol. 2015;68:35-9.
55. Singhal S, Bhojnagarwala PS, O'Brien S, Moon EK, Garfall AL, Rao AS, et al. Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. Cancer Cell. 2016;30:120-35.
56. Kargl J, Busch SE, Yang GH, Kim KH, Hanke ML, Metz HE, et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun. 2017;8:14381.
57. Kortlever RM, Sodir NM, Wilson CH, Burkhart DL, Pellegrinet L, Brown Swigart L, et al. Myc cooperates with Ras by programming inflammation and immune suppression. Cell. 2017;171:1301-15 e14.
58. Greillier L, Tomasini P, Barlesi F. Necitumumab for non-small cell lung cancer. Expert Opin Biol Ther. 2015;15:1231-9.
59. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012;13:33-42.
60. Crawford J, Swanson P, Schwarzenberger P, Sandler A, Prager D, Zhang K, et al. A phase 2 randomized trial of Paclitaxel and Carboplatin with or without Panitumumab for first-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2013;8:1510-8.
61. Schuette W, Behringer D, Stoehlmacher J, Kollmeier J, Schmager S, Fischer von Weikersthal L, et al. CHAMP: A phase II study of Panitumumab with Pemetrexed and Cisplatin versus Pemetrexed and Cisplatin in the treatment of patients with advanced-stage primary nonsquamous non-small-cell lung cancer with particular regard to the KRAS status. Clin Lung cancer. 2015;16:447-56.
62. Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et al. Panitumumab versus Cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014;15:569-79.
63. Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, et al. Activating Fcγ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013;210:1685-93.
64. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210:1695-710.
65. Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell. 2018.
66. Turaj AH, Hussain K, Cox KL, Rose-Zerilli MJJ, Testa J, Dahal LN, et al. Antibody tumor targeting is enhanced by CD27 agonists through myeloid recruitment. Cancer Cell. 2017;32:777-91 e6.
67. Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the 'high-hanging fruit'. Nat Rev Drug Discov. 2017,17:197-223.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341
Published OnlineFirst October 3, 2018.Mol Cancer Ther Thies Rösner, Steffen Kahle, Francesca Montenegro, et al. EGFRImmune effector functions of human IgG2 antibodies against
Updated version
10.1158/1535-7163.MCT-18-0341doi:
Access the most recent version of this article at:
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 3, 2018; DOI: 10.1158/1535-7163.MCT-18-0341